Condition: Surgical Wound Infection · Traumatic Wound Infection · Sponsor: Macro Biologics, Inc.
The goal of this Phase 1 clinical trial is to learn about the safety profile of Amicidin-β topical solution applied directly into infected surgical or traumatic wounds during a surgical procedure. The main questions it aims to answer are: 1. Is Amicidin-β topical solution safe to test in larger clinical trials? 2. Is Amicidin-β topical solution absorbed into the bloodstream from local wound application? 3. Is Amicidin-β topical solution easy for the surgeon to use? Participants will receive either standard of care alone, or standard of care with intrawound Amicidin-β topical solution for the management of their wound infection. Researchers will compare these two groups (standard of care alone to standard of care with Amicidin-β topical solution) to see if there are any study drug-related adverse effects.
This description comes directly from the study's public registry record.
Daniel J Gowen-Huang, MBA · (323) 717-0302 · dgowenhuang@macrobiologics.com
Michael P Bevilacqua, MD, PhD · (303) 881-5169 · mpb@macrobiologics.com
Always discuss trial participation with your own doctor first.
| Lundquist Institute | Torrance, California, United States | Recruiting |
| Snake River Research, PLLC | Idaho Falls, Idaho, United States | Recruiting |
| LifeBridge Health | Baltimore, Maryland, United States | Recruiting |
| Washington University in St. Louis | St Louis, Missouri, United States | Recruiting |
| The Ohio State University | Columbus, Ohio, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07379684